Acute Toxicity Evaluation of a new Benzimidazole derivative on the wistar rat

Abstract

3-[2-(1H-Benzimidazol-2-ylsulfanyl)-ethyl]-1,3-oxazolidin-2-one (OXB1) is a new Benzimidazole derivative which was synthesized in our laboratory then characterized with several physicochemical techniques. However, its related toxic effect remains unknown. The present work aims to study its acute toxicity in normal Wistar rats. Six groups of rats received an intrapéritonéale (i.p.) injection of different doses of OXB1 (500, 700, 900, 1000 and 1200mg/kg) and were daily monitored for 14 days. Mortalities, changes in food and water uptake, behavioral changes and weight were monitored. The OXB1 Lethal Dose 50 (LD50) was 1084mg/kg. The administration of the studied molecule at a dose of 900mg/kg did not affect animal viability and body weight (bw). In addition, food and water intake are unchanged. Furthermore, at the this dose, the levels of hematological and biochemical values and organ’s weights were not affected which confirm that the No-Observed-Adverse-Effect Level (NOAEL) dose of OXB1 is 900 mg/kg in normal Wistar rats and could possibly be tested after further analysis in a preliminary clinical test.